Provide molecular diagnostic tests for evaluating cancer risk, primarily in the United States. Now — the numbers.
This is an established company with proven profits.
If every debt were paid off today, $1.3M would still be left in the vault — a solid cushion for hard times.
The market pays 1.5× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are going backwards, not just slowing.
An investor who bought at the very peak is down 86% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 63% — still a thick cushion, though costs have been eating into it lately.
There is $2.5M in the vault; even if every debt were paid off, $1.3M would remain.
Over the last 12 months, company executives reported 18 buys and 5 sells. Management buying with its own money is usually read as a good sign.
Over the last 4 years, sales fell about 2% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.